— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) Disorders — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Source: Veralox Frederick, MD, Aug. 14, 2024 – Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan … Read more
Startup
Exploring InfoPathways and their remarkable support of FITCI and the entrepreneurs we serve! This partnership, sparked by a referral, has blossomed into a powerful alliance, showcasing InfoPathways’ unwavering commitment to nurturing emerging businesses and fostering a vibrant, economically healthy community. Theresa Bethune, founder of InfoPathways, connected with FITCI through one of our startup clients who … Read more
By Anna Eyler In a rapidly evolving business landscape, startups that don’t consider implementing emerging technologies like artificial intelligence (AI) and robotics into their operations are at risk of being left behind. Leveraging these tools allows employees to spend more time and energy on strategic tasks that require high-level critical thinking. By integrating AI-driven algorithms … Read more
Experience the Future in Every Dimension at FITCI’s spectacular launch celebration of Maryland’s EDGE at 321 Ballenger Center Drive in Frederick, Maryland. Join the journey into the future of innovation in Frederick as we unveil our brand-new space designed to inspire innovation, collaboration, and breakthrough discoveries. Highlights include lots of surprises, and tours of our … Read more
FITCI Grad builds upon an unprecedented three Breakthrough Medical Device designations by the FDA Theradaptive, a leading biopharmaceutical company using protein engineering to create targeted therapeutics, has been awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies. Awarded … Read more
Budding entrepreneurs and seasoned business leaders gathered at FITCI’s ROOT location in downtown Frederick, Mayrland, for the first installment of the incubator’s newest community program, the IDEA Lab, sponsored by the Truist Foundation. Session leader/mentor Robert “Bob” Stoneking of Pachydermos began the evening event by telling participants, “the purpose of the IDEA Lab is not … Read more
CarrTech Corporation performed its human factor trials with local healthcare professionals at FITCI’s Metropolitan Court location May 17th through 28th, moving their all-in-one package filter and hypodermic needle product, F.R.O.G (filter removal of glass), closer to market. This practical testing enlisted 20 study participants with experience using glass ampoule-based medications (i.e., #physicians, #pharmacists, #nurses). The … Read more
Sam Glickstein, CEO of FITCI client Osprey BioScience, announced that the company officially launched their flagship product – CloneCard. The patent-pending item is a proprietary nucleic acid storage and delivery (at room temperature) system. It offers researchers the ability to start building multi-genic and multi-modal therapeutic candidates modularly, in less time and with lower costs. … Read more
KnowledgeNet.ai and LeadLander are thrilled to announce that they have teamed up to make a powerful collaborative solution available for customers in the fields of prospect research and business development. KnowledgeNet.ai, the AI-relationship intelligence tool for business that connects siloed interactions and information, is excited to combine its organization-wide view of past and present contacts … Read more
Congratulations #FITCI Grad Theradaptive on your ICON Award win! The Maryland Tech Council, the largest technology and life science trade association in the state, announced the winners of its 2023 ICON Awards on April 28, 2023, hailing Frederick’s own Theradaptive as its “Emerging Life Sciences Company of the Year.” Kelly Schulz, CEO of the Maryland … Read more


